Patents by Inventor Punit P. Seth

Punit P. Seth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGOMERIC COMPOUNDS COMPRISING ALPHA-BETA-CONSTRAINED NUCLEIC ACID
    Publication number: 20190359979
    Abstract: The present disclosure provides oligomeric compounds comprising at least one ?-?-constrained nucleic acid as provided herein. More particularly, the ?-?-constrained nucleic acid provided herein comprise an optionally modified nucleoside with a phosphorus containing constrained internucleoside linkage such as for example a cyclic phosphate internucleoside linkage. The ?-?-constrained nucleic acid provided herein are expected to be useful for enhancing one or more properties of oligomeric compounds they are incorporated into such as for example nuclease resistance. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: January 4, 2019
    Publication date: November 28, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Eric E. Swayze, Punit P. Seth
  • SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
    Publication number: 20190338281
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Application
    Filed: December 17, 2018
    Publication date: November 7, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaaard, Eric E. Swayze
  • COMPOUNDS AND METHODS FOR USE IN DYSTROPHIN TRANSCRIPT
    Publication number: 20190330626
    Abstract: Provided herein are methods, compounds, and compositions for modulation of dystrophin pre-mRNA in an animal. Such methods, compounds, and compositions are useful, for example, to treat, prevent, or ameliorate one or more symptoms of Duchenne Muscular Dystrophy disease.
    Type: Application
    Filed: July 17, 2017
    Publication date: October 31, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Frank Rigo, Thazha P. Prakash, Punit P. Seth
  • COMPOUNDS AND METHODS FOR MODULATION OF TRANSCRIPT PROCESSING
    Publication number: 20190321387
    Abstract: Provided herein are methods, compounds, and compositions for modulation of transcript processing.
    Type: Application
    Filed: July 17, 2017
    Publication date: October 24, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Frank Rigo, Punit P. Seth
  • COMPOUNDS AND METHODS FOR MODULATION OF SMN2
    Publication number: 20190323006
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of spinal muscular atrophy.
    Type: Application
    Filed: July 17, 2017
    Publication date: October 24, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Frank Rigo, Thazha P. Prakash, Punit P. Seth
  • Allele specific modulators of P23H rhodopsin
    Patent number: 10426789
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject. The present embodiments provided herein are directed to compounds and compositions useful for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP). In certain embodiments, P23H rhodopsin inhibitors provided herein are allele-specific antisense compounds targeted to a P23H mutant allele that are capable of selectively inhibiting expression of P23H rhodopsin mutant protein to a greater extent than wild-type protein.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: October 1, 2019
    Inventors: Susan F. Murray, Punit P. Seth, Michael L. McCaleb, Susan M. Freier, Priyam Singh
  • SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
    Publication number: 20190276823
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount, activity, or expression of the target nucleic acid in a cell. In certain embodiments, hybridization results in selective modulation of the amount, activity, or expression of a target Huntingtin gene or Huntingtin transcript in a cell.
    Type: Application
    Filed: September 25, 2018
    Publication date: September 12, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Punit P. Seth, Eric E. Swayze
  • ANTISENSE COMPOUNDS AND USES THEREOF
    Publication number: 20190270990
    Abstract: The present disclosure provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Application
    Filed: October 22, 2018
    Publication date: September 5, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Holly Kordasiewicz, Curt Mazur, Punit P. Seth, Eric E. Swayze
  • METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS
    Publication number: 20190209694
    Abstract: Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.
    Type: Application
    Filed: September 7, 2018
    Publication date: July 11, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Michael T. Migawa, Jinghua Yu, W. Brad Wan, Sayten P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Linkage modified oligomeric compounds
    Patent number: 10344275
    Abstract: The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. Such oligomeric compounds have enhanced stability to exposure to base during synthesis. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: July 9, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: W. Brad Wan, Michael T. Migawa, Michael Oestergaard, Eric E. Swayze, Punit P. Seth
  • COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION
    Publication number: 20190160090
    Abstract: Disclosed herein are compositions and compounds comprising modified oligonucleotides for modulating AGT and modulating a RAAS pathway related disease, disorder and/or condition in an individual in need thereof. A RAAS pathway related disease, disorder and/or condition in an individual such as hypertension can be treated, ameliorated, delayed or prevented with the administration of antisense compounds targeted to AGT.
    Type: Application
    Filed: October 7, 2016
    Publication date: May 30, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Adam Mullick, Mark J. Graham, Punit P. Seth, Susan M. Freier
  • Compounds and methods for the modulation of COMP
    Patent number: 10287584
    Abstract: In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. In certain embodiments, the target nucleic acid is a nucleic acid that encodes cartilage oligomeric matrix protein. In certain embodiments, the target nucleic acid is a nucleic acid expressed in the growth plate, tendon, or cartilage.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: May 14, 2019
    Assignees: IONIS PHARMACEUTICALS, INC., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Shuling Guo, Punit P. Seth, Jacqueline T. Hecht, Karen LaShea Posey
  • GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
    Publication number: 20190134214
    Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.
    Type: Application
    Filed: May 4, 2017
    Publication date: May 9, 2019
    Inventors: Brett P. Monia, Thazha P. Prakash, Garth A. KINBERGER, Richard Lee, Punit P. Seth, Shalini Andersson, Eva Carina Ämmälä, Daniel Laurent Knerr, Maria Astrid Ölwegård-Halvarsson, Eric Valeur, William John Drury III
  • Compositions and methods for modulating complement factor B expression
    Patent number: 10280423
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: May 7, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Tamar R. Grossman, Michael L. McCaleb, Susan M. Freier
  • Selective antisense compounds and uses thereof
    Patent number: 10260069
    Abstract: The present disclosure provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. In certain embodiments, certain oligomeric compounds selectively reduce the expression of a target nucleic acid transcript relative to a non-target nucleic acid transcript.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: April 16, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Punit P. Seth, Eric E. Swayze
  • Oligomeric compounds comprising alpha-beta-constrained nucleic acid
    Patent number: 10221416
    Abstract: The present disclosure provides oligomeric compounds comprising at least one ?-?-constrained nucleic acid as provided herein. More particularly, the ?-?-constrained nucleic acid provided herein comprise an optionally modified nucleoside with a phosphorus containing constrained internucleoside linkage such as for example a cyclic phosphate internucleoside linkage. The ?-?-constrained nucleic acid provided herein are expected to be useful for enhancing one or more properties of oligomeric compounds they are incorporated into such as for example nuclease resistance. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: March 5, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Eric E. Swayze, Punit P. Seth
  • COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
    Publication number: 20190055554
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Application
    Filed: February 14, 2018
    Publication date: February 21, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Selective antisense compounds and uses thereof
    Patent number: 10202599
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: February 12, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaard, Eric E. Swayze
  • COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION
    Publication number: 20190016748
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.
    Type: Application
    Filed: February 26, 2018
    Publication date: January 17, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Mark J. Graham, Rosanne M. Crooke
  • MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
    Publication number: 20180371005
    Abstract: The present invention provides modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides and analogs thereof that are useful for incorporation at the terminus of an oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: August 30, 2018
    Publication date: December 27, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze